Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKYAOTCMKTS:INISNYSE:INTTNASDAQ:NAUT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKYAAkoya Biosciences$1.32+1.5%$1.21$0.93▼$3.42$64.94M1.36401,251 shs530,385 shsINISInternational Isotopes$0.08+5.2%$0.05$0.03▼$0.08$40.53M0.84255,574 shs136,025 shsINTTinTEST$7.26-0.3%$6.45$5.24▼$11.92$90.71M1.6252,310 shs17,908 shsNAUTNautilus Biotechnology$0.73+0.7%$0.74$0.66▼$3.09$91.44M1.42159,118 shs423,420 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKYAAkoya Biosciences+4.84%+0.78%+5.26%-3.70%-44.44%INISInternational Isotopes+10.16%+29.41%+50.68%+67.39%+175.00%INTTinTEST-1.62%+5.20%+20.33%+6.28%-26.32%NAUTNautilus Biotechnology+4.50%+4.29%-2.71%-12.67%-69.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKYAAkoya Biosciences2.1613 of 5 stars3.03.00.00.02.01.70.6INISInternational Isotopes0.4649 of 5 stars0.05.00.00.00.60.80.0INTTinTEST3.4877 of 5 stars3.33.00.00.02.73.31.3NAUTNautilus Biotechnology2.4547 of 5 stars2.52.00.00.03.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKYAAkoya Biosciences 2.00Hold$2.5189.85% UpsideINISInternational Isotopes 0.00N/AN/AN/AINTTinTEST 2.67Moderate Buy$12.0065.29% UpsideNAUTNautilus Biotechnology 1.00Sell$2.13191.10% UpsideCurrent Analyst Ratings BreakdownLatest INIS, NAUT, INTT, and AKYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.80 ➝ $1.085/5/2025INTTinTESTNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025INTTinTESTLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.004/29/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$3.50 ➝ $1.804/14/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.65(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKYAAkoya Biosciences$81.67M0.81N/AN/A$0.15 per share8.80INISInternational Isotopes$13.90M3.07$0.00 per share98.35$0.01 per share8.10INTTinTEST$127.50M0.71$1.26 per share5.75$7.92 per share0.92NAUTNautilus BiotechnologyN/AN/AN/AN/A$1.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKYAAkoya Biosciences-$55.37M-$0.97N/AN/AN/A-59.44%-487.85%-35.86%8/4/2025 (Estimated)INISInternational Isotopes$10KN/A0.00∞N/A0.35%1.21%0.30%8/12/2025 (Estimated)INTTinTEST$9.34M-$0.0131.5718.15N/A2.33%5.31%3.42%N/ANAUTNautilus Biotechnology-$70.78M-$0.54N/AN/AN/AN/A-31.87%-27.39%7/29/2025 (Estimated)Latest INIS, NAUT, INTT, and AKYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025NAUTNautilus Biotechnology-$0.14N/AN/AN/AN/AN/A5/12/2025Q1 2025AKYAAkoya Biosciences-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 million5/2/2025Q1INTTinTEST-$0.10-$0.11-$0.01N/AN/AN/A4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKYAAkoya BiosciencesN/AN/AN/AN/AN/AINISInternational IsotopesN/AN/AN/AN/AN/AINTTinTESTN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKYAAkoya Biosciences10.120.610.40INISInternational Isotopes0.060.990.83INTTinTEST0.082.261.38NAUTNautilus BiotechnologyN/A17.3617.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKYAAkoya Biosciences79.42%INISInternational IsotopesN/AINTTinTEST63.18%NAUTNautilus Biotechnology50.71%Insider OwnershipCompanyInsider OwnershipAKYAAkoya Biosciences7.30%INISInternational Isotopes18.10%INTTinTEST7.00%NAUTNautilus Biotechnology41.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKYAAkoya Biosciences9049.95 million46.31 millionOptionableINISInternational Isotopes30526.39 million431.11 millionNot OptionableINTTinTEST32012.50 million11.69 millionOptionableNAUTNautilus Biotechnology130126.15 million74.30 millionOptionableINIS, NAUT, INTT, and AKYA HeadlinesRecent News About These CompaniesInsiders of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) have had a great week after last week's US$12m gain and they haven't stopped buyingJune 27, 2025 | finance.yahoo.comNautilus Biotechnology Leads The Pack In Our Top 3 Penny StocksJune 27, 2025 | finance.yahoo.comInsider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CFO Purchases 15,000 Shares of StockJune 3, 2025 | marketbeat.comNautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | tmcnet.comNautilus Biotechnology And 2 Other Penny Stocks With Promising PotentialMay 15, 2025 | uk.finance.yahoo.comEarnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beatMay 1, 2025 | uk.investing.comNautilus Biotechnology Inc (NAUT) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions ...April 30, 2025 | finance.yahoo.comWhy Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 7.04%April 30, 2025 | aaii.comANautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call TranscriptApril 30, 2025 | msn.comQ1 2025 Nautilus Biotechnology Inc Earnings CallApril 30, 2025 | uk.finance.yahoo.comNautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancementsApril 29, 2025 | msn.comNautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comNautilus Biotechnology Reports First Quarter 2025 Financial ResultsApril 29, 2025 | manilatimes.netMNautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025April 18, 2025 | seekingalpha.comWhy Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 10.19%April 9, 2025 | aaii.comAWe're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateApril 1, 2025 | finance.yahoo.comInsider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Purchases 53,300 Shares of StockMarch 22, 2025 | insidertrades.comGlobal Research Antibodies Market Poised for Remarkable Growth, Projected to Reach USD 9.6 Billion by 2032 | FMIMarch 4, 2025 | fmiblog.comFNautilus Biotechnology price target lowered to $2.50 from $4 at GuggenheimFebruary 28, 2025 | markets.businessinsider.comNautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comNautilus Biotechnology Inc (NAUT) Q4 2024 Earnings Call Highlights: Progress in Proteome ...February 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINIS, NAUT, INTT, and AKYA Company DescriptionsAkoya Biosciences NASDAQ:AKYA$1.32 +0.02 (+1.54%) Closing price 04:00 PM EasternExtended Trading$1.30 -0.02 (-1.14%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.International Isotopes OTCMKTS:INIS$0.08 +0.00 (+5.19%) As of 02:14 PM EasternInternational Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through four segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.inTEST NYSE:INTT$7.26 -0.02 (-0.27%) Closing price 04:00 PM EasternExtended Trading$7.22 -0.04 (-0.48%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.inTEST Corporation provides test and process technology solutions for use in manufacturing and testing in automotive, defense/aerospace, industrial, life sciences, security, and semiconductor markets worldwide. The company operates through three segments: Electronic Test, Environmental Technologies, and Process Technologies. The Electronic Test segment offers in2, Cobal, and LS series manipulators that hold various test heads and enable an operator to reposition a test head for alternate use with various probers or handlers on a test floor; and docking hardware products, which protect the interface contacts and ensure proper repeatable and precise alignment between the test head's interface board and the prober's probing assembly. This segment also provides tester interfaces that offer electrical connections between the tester and the wafer prober or IC handler; scorpion flying probe test systems that designs and manufactures robotics-based electronic test equipment; and BRiZ automated test and programming services. Its products are used in production testing of wafers and specialized packaged ICs in back-end testing by semiconductor manufacturers. The Environmental Technologies segment provides ThermoStream products that are used in the semi market as a stand-alone temperature management tool, or in various electronic test applications; thermal chambers; thermal platforms; Thermonics temperature conditioning products that offer tempered gas or fluid; and ultra-cold storage solutions, including biomedical freezers, refrigerators, and mobile storage solutions. The Process Technologies segment offers EKOHEAT and EASYHEAT induction heating systems; and digital streaming and image capturing solutions. The company markets and sells its products to semiconductor manufacturers, third-party foundries, test and assembly providers, and original equipment manufacturers. inTEST Corporation was incorporated in 1981 and is headquartered in Mount Laurel, New Jersey.Nautilus Biotechnology NASDAQ:NAUT$0.73 +0.01 (+0.70%) Closing price 04:00 PM EasternExtended Trading$0.73 +0.00 (+0.41%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
